199 related articles for article (PubMed ID: 11756579)
1. Octreotide therapy for tumor-induced osteomalacia.
Seufert J; Ebert K; Müller J; Eulert J; Hendrich C; Werner E; Schuüze N; Schulz G; Kenn W; Richtmann H; Palitzsch KD; Jakob F
N Engl J Med; 2001 Dec; 345(26):1883-8. PubMed ID: 11756579
[No Abstract] [Full Text] [Related]
2. Octreotide for tumor-induced osteomalacia.
Paglia F; Dionisi S; Minisola S
N Engl J Med; 2002 May; 346(22):1748-9; author reply 1748-9. PubMed ID: 12037159
[No Abstract] [Full Text] [Related]
3. Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia.
Duet M; Kerkeni S; Sfar R; Bazille C; Lioté F; Orcel P
Clin Nucl Med; 2008 Nov; 33(11):752-6. PubMed ID: 18936605
[TBL] [Abstract][Full Text] [Related]
4. Targeted FGFR Blockade for the Treatment of Tumor-Induced Osteomalacia.
Hartley IR; Miller CB; Papadakis GZ; Bergwitz C; Del Rivero J; Blau JE; Florenzano P; Berglund JA; Tassone J; Roszko KL; Moran S; Gafni RI; Isaacs R; Collins MT
N Engl J Med; 2020 Oct; 383(14):1387-1389. PubMed ID: 32905668
[No Abstract] [Full Text] [Related]
5. [Tumor-induced hypophosphatemic osteomalacia].
Ito N; Fukukmoto S
Nihon Naika Gakkai Zasshi; 2007 Apr; 96(4):731-6. PubMed ID: 17506312
[No Abstract] [Full Text] [Related]
6. [Detection of the primary tumor site in tumor-induced osteomalacia by indium-111 octreotide scintigraphy: a case report].
Takahashi M; Toru S; Ota K; Izumiyama H; Yokota T; Mizusawa H
Rinsho Shinkeigaku; 2008 Feb; 48(2):120-4. PubMed ID: 18326305
[TBL] [Abstract][Full Text] [Related]
7. The levels of somatostatin receptors in causative tumors of oncogenic osteomalacia are insufficient for their agonist to normalize serum phosphate levels.
Ishii A; Imanishi Y; Kobayashi K; Hashimoto J; Ueda T; Miyauchi A; Koyano HM; Kaji H; Saito T; Oba K; Komatsu Y; Kurajoh M; Nagata Y; Goto H; Wakasa K; Sugimoto T; Miki T; Inaba M; Nishizawa Y
Calcif Tissue Int; 2010 Jun; 86(6):455-62. PubMed ID: 20458578
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic osteomalacia: two case reports with surprisingly different outcomes.
Seijas R; Ares O; Sierra J; Pérez-Dominguez M
Arch Orthop Trauma Surg; 2009 Apr; 129(4):533-9. PubMed ID: 19125258
[TBL] [Abstract][Full Text] [Related]
9. Dual paraneoplastic syndromes: small cell lung carcinoma-related oncogenic osteomalacia, and syndrome of inappropriate antidiuretic hormone secretion: report of a case and review of the literature.
Tantisattamo E; Ng RC
Hawaii Med J; 2011 Jul; 70(7):139-43. PubMed ID: 21886301
[TBL] [Abstract][Full Text] [Related]
10. [Tumor-induced rickets/osteomalacia].
Fukumoto S
Nihon Rinsho; 2005 Oct; 63 Suppl 10():523-8. PubMed ID: 16279694
[No Abstract] [Full Text] [Related]
11. Tumor-induced Osteomalacia in a 3-Year-Old With Unresectable Central Giant Cell Lesions.
Crossen SS; Zambrano E; Newman B; Bernstein JA; Messner AH; Bachrach LK; Twist CJ
J Pediatr Hematol Oncol; 2017 Jan; 39(1):e21-e24. PubMed ID: 27820122
[TBL] [Abstract][Full Text] [Related]
12. Octreotide Is Ineffective in Treating Tumor-Induced Osteomalacia: Results of a Short-Term Therapy.
Ovejero D; El-Maouche D; Brillante BA; Khosravi A; Gafni RI; Collins MT
J Bone Miner Res; 2017 Aug; 32(8):1667-1671. PubMed ID: 28459498
[TBL] [Abstract][Full Text] [Related]
13. [Tumor-induced rickets/osteomalacia].
Fukumoto S
Nihon Rinsho; 2006 Jun; Suppl 2():96-9. PubMed ID: 16817359
[No Abstract] [Full Text] [Related]
14. [Hypophosphatemic osteomalacia].
Bullmann C; Benker G; Rosien U; Delling G; Siggelkow H; Schulte HM
Med Klin (Munich); 2008 Sep; 103(9):671-5. PubMed ID: 18813890
[TBL] [Abstract][Full Text] [Related]
15. Osteomalacia induced by a phosphaturic mesenchymal tumor secreting fibroblast growth factor 23.
Nagae K; Uchi H; Ito T; Moroi Y; Oda Y; Furue M
Eur J Dermatol; 2015 Apr; 25(2):199-200. PubMed ID: 25788099
[No Abstract] [Full Text] [Related]
16. Cinacalcet in the management of tumor-induced osteomalacia.
Geller JL; Khosravi A; Kelly MH; Riminucci M; Adams JS; Collins MT
J Bone Miner Res; 2007 Jun; 22(6):931-7. PubMed ID: 17352646
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour-induced osteomalacia.
Ito N; Shimizu Y; Suzuki H; Saito T; Okamoto T; Hori M; Akahane M; Fukumoto S; Fujita T
J Intern Med; 2010 Oct; 268(4):390-4. PubMed ID: 20698924
[No Abstract] [Full Text] [Related]
18. Tumour-induced osteomalacia: An emergent paraneoplastic syndrome.
Alonso G; Varsavsky M
Endocrinol Nutr; 2016 Apr; 63(4):181-6. PubMed ID: 26718193
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptor expression in an epitheloid hemangioma causing oncogenic osteomalacia.
Müssig K; Oksüz MO; Pfannenberg C; Adam P; Zustin J; Beckert S; Petersenn S
J Clin Endocrinol Metab; 2009 Nov; 94(11):4123-4. PubMed ID: 19789203
[No Abstract] [Full Text] [Related]
20. Indium-111 pentetreotide scintigraphy of mesenchymal tumor with oncogenic osteomalacia.
Nguyen BD; Wang EA
Clin Nucl Med; 1999 Feb; 24(2):130-1. PubMed ID: 9988077
[No Abstract] [Full Text] [Related]
[Next] [New Search]
